Health and Healthcare
Teva Launches Generic Seroquel on First Day of Patent Loss (TEVA, AZN)
Published:
Last Updated:
We noted earlier today that AstraZeneca plc (NYSE: AZN) had lost a patent ruling and that the company’s anti-pyschotic drug Seroquel lost its patent protection today. That’s all it took for Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA) to kick out its quetiapine generic for Seroquel.
Teva’s price sheet shows the difference a patent makes in the UK. An equal supply of 100-mg coated tablets of Seroquel costs about $180 compared with the generic cost of about $27. In its announcement, Teva notes that it has released 10 new products in 11 weeks, and 7 of those came on the first day of patent expiration.
Teva’s announcement is available here.
The company’s share price is up about 1.5% at $43.72 in a 52-week range of $35.00-$51.30.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
